What is Kymera Therapeutics's D&A?

Kymera Therapeutics (KYMR) reported D&A of $2.02M in Q1 2026.

How has Kymera Therapeutics's D&A changed year-over-year?

Kymera Therapeutics's D&A decreased by 1.3% year-over-year, from $2.05M to $2.02M.

What is the long-term trend for Kymera Therapeutics's D&A?

Over 4 years (2021 to 2025), Kymera Therapeutics's D&A has grown at a 36.5% compound annual growth rate (CAGR), from $2.4M to $8.31M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Kymera Therapeutics KYMR D&A

D&A at other companies

PfizerPFE

$1.61B-0.3%

Johnson & JohnsonJNJ

$2B+13.1%

Regeneron PharmaceuticalsREGN

$123.2M-2.9%

ImmunityBio, Inc.IBRX

$4.38M+14.4%

Krystal Biotech, Inc.KRYS

$1.52M+7.9%

Protagonist TherapeuticsPTGX

——

Other financials

Income statement

See full

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

See full

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total equity$1.5B+95.8%

Total assets$1.7B+81.7%

Cash flow

See full

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

See full

Market cap$7.44B+283%

Enterprise value$7.38B+280%

P/S144.5×+111×

Profitability

See full

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

See full

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kymera Therapeutics's D&A?: Kymera Therapeutics (KYMR) reported D&A of $2.02M in Q1 2026.
How has Kymera Therapeutics's D&A changed year-over-year?: Kymera Therapeutics's D&A decreased by 1.3% year-over-year, from $2.05M to $2.02M.
What is the long-term trend for Kymera Therapeutics's D&A?: Over 4 years (2021 to 2025), Kymera Therapeutics's D&A has grown at a 36.5% compound annual growth rate (CAGR), from $2.4M to $8.31M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.